Cas:957061-11-9 2-Chloro-3-(trifluoromethyl)phenylboronic acid manufacturer & supplier

Chemical Name:2-Chloro-3-(trifluoromethyl)phenylboronic acid

CAS.NO:957061-11-9

Synonyms:[2-chloro-3-(trifluoromethyl)phenyl]boronic acid

Molecular Formula:C₇H₅BClF₃O₂

Molecular Weight:224.37300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:313.5ºC at 760 mmHg

Density:1.49g/cm3

Index of Refraction:1.484

PSA:40.46000

Exact Mass:224.00200

LogP:1.03860

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like [2-chloro-3-(trifluoromethyl)phenyl]boronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[2-chloro-3-(trifluoromethyl)phenyl]boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[2-chloro-3-(trifluoromethyl)phenyl]boronic acid Use and application,[2-chloro-3-(trifluoromethyl)phenyl]boronic acid technical grade,usp/ep/jp grade.

Related News: Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 2-Chloro-3-(trifluoromethyl)phenylboronic acid manufacturer The South Korean government is banning entry to all foreign nationals who visited China’s Hubei province in the past 14 days. 2-Chloro-3-(trifluoromethyl)phenylboronic acid supplier As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 2-Chloro-3-(trifluoromethyl)phenylboronic acid vendor Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 2-Chloro-3-(trifluoromethyl)phenylboronic acid factory Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview.